|5th October 2020||Eric Dobmeier||46,337||Grant/award etc.||$0.00|
|5th October 2020||Davis Jerel||722,247||Grant/award etc.||$0.00|
|5th October 2020||Davis Jerel||4,733,023||Grant/award etc.||$0.00|
|5th October 2020||Davis Jerel||730,470||Grant/award etc.||$0.00|
|5th October 2020||Srinivas Akkaraju||3,168,388||Grant/award etc.||$0.00|
|5th October 2020||Tom Frohlich||153,398||Grant/award etc.||$0.00|
|5th October 2020||Davis Jerel||2,433,099||Grant/award etc.||$0.00|
|1st October 2020||Eric Dobmeier||776||Open or private sale||$49.21||$38,186.96|
|1st October 2020||Eric Dobmeier||9,224||Open or private sale||$48.47||$447,087.28|
|1st October 2020||Eric Dobmeier||10,000||Exercise of derivative||$6.32||$63,200.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.
Aduro BioTech, Inc. is a clinical-stage immunotherapy company. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD. The company's platforms stimulate and/or regulate innate and adaptive immune responses.